Electronic Supplementary Information

Pyridazinediones deliver potent, stable, targeted and efficacious antibody-drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody

Eifion Robinson,‡a João P. M. Nunes,‡a Vessela Vassileva, b Antoine Maruani, Mark E. B. Smith, R. Barbara Pedley, b Stephen Caddick, a James R. Baker* a and Vijay Chudasama* a

aDepartment of Chemistry, University College London, London, WC1H 0AJ, UK. Tel.: +44 (0)20 7679 2653 and + 44 (0)20 7679 2077; E-mail: j.r.baker@ucl.ac.uk and v.chudasama@ucl.ac.uk
bUCL Cancer Institute, 72 Huntley Street, London, WC1E 6BT, UK

‡These authors contributed equally to this work.
Sections Included

Conjugation Experiments General Remarks ................................................................. 4
Analytical methods for antibody-drug conjugates ......................................................... 5
  SDS-PAGE .................................................................................................................. 5
  Determination of concentrations for trastuzumab NGM and PD ADCs ..................... 5
  Liquid chromatography mass spectrometry (LC-MS) ............................................... 6
  Hydrophobic interaction chromatography (HIC) ....................................................... 6
  Size-exclusion chromatography (SEC) ....................................................................... 7
  Enzyme-linked immunosorbent assay (ELISA) ......................................................... 7
Alexa Fluor 488® conjugate serum stability ................................................................. 8
Determination of fluorophore to antibody ratio (FAR) ............................................... 8
Cell Lines .................................................................................................................... 8
In Vitro Cytotoxicity Assessment .................................................................................. 9
In Vivo Efficacy Assessment ......................................................................................... 9
Statistical Analyses ....................................................................................................... 10
Conjugation protocols .................................................................................................... 11
  Figure S1 – Reagents used for conjugation ............................................................... 11
  Conjugation of trastuzumab with NGM-MMAE 6 (NGM-MMAE ADC 1) ................ 12
  Conjugation of trastuzumab with Mal-MMAE 7 (Mal-MMAE ADC 2) ...................... 12
  Conjugation of trastuzumab with PD-MMAE 8 (PD-MMAE ADC 3) ....................... 12
  Conjugation of trastuzumab with PD-MMAE 9 (PD-MMAE ADC 4) ....................... 13
  Conjugation of trastuzumab with PD-propargylamide 10, followed by copper-catalysed Huisgen 1,3-dipolar cycloaddition (CuAAC) with Alexa Fluor 488® (conjugate AFC 5) .......................................................... 13
  Conjugation of trastuzumab with Mal-propargylamide 11, followed by copper-catalysed Huisgen 1,3-dipolar cycloaddition (CuAAC) with Alexa Fluor 488® (conjugate AFC 12) .......................................................... 13
  Conjugation of albumin with Mal-propargylamide 11, followed by copper-catalysed Huisgen 1,3-dipolar cycloaddition (CuAAC) with Alexa Fluor 488® (used as control for serum stability study) .......................................................... 14
Supplementary figures and tables .................................................................................. 15
  Figure S2 – LC-MS data of unmodified trastuzumab ............................................... 15
  Figure S3 – LC-MS data of PD-MMAE ADC 3 ....................................................... 16
  Figure S4 – LC-MS data of PD-MMAE ADC 4 ....................................................... 17
  Figure S5 – SEC-HPLC chromatograms of trastuzumab, NGM-MMAE ADC XX and Mal-MMAE ADC XX .............................................................. 18
  Figure S6 – HER2 ELISA of PD-MMAE ADC 3 & 4 compared with trastuzumab .... 20
  Figure S7 – SEC-HPLC chromatograms of serum stability study with AFC 5 and AFC 12 ...... 21
Synthesis General Remarks ......................................................................................... 22
Synthesis of compounds ............................................................................................... 23
  Scheme S1 – Synthesis of Mal-MMAE 6 ............................................................... 23
  Scheme S2 – Synthesis of PD-MMAE 9 and Mal-propargylamide 11 ..................... 24
  Scheme S3 – Synthesis of PD-MMAE 8 and PD-propargylamide 10 ....................... 25
  tert-butyl-46-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-41-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxa-40-azahexatetracontanoate 14 ............... 26
  Maleimide-C6-PEG312-tert-butyl ester 14 .............................................................. 26
  Mal-MMAE 7 ........................................................................................................... 28
  2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid 15 ........................................... 30
**Conjugation Experiments General Remarks**

Conjugation experiments were carried out in standard polypropylene micro test tubes at atmospheric pressure with mixing at 20 °C unless otherwise stated. Reagents and solvents were purchased from commercial sources and used as supplied. All buffer solutions were prepared with double-deionised water and filter-sterilised. Borate-buffered saline (BBS) was 25 mM sodium borate, 25 mM sodium chloride and 1 mM EDTA at pH 8.0. Phosphate-buffered saline (PBS) was 140 mM sodium chloride and 12 mM sodium phosphates at pH 7.4. Phosphate-buffered saline for SEC-HPLC was 140 mM NaCl, 100 mM sodium phosphates and 0.02% sodium azide at pH 7.0. Ultrapure DMF was purchased from Sigma-Aldrich and kept under dry conditions. Solutions of tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 10 mM (2.87 mg/mL) were prepared in BBS. Filtration of particulates was carried out through Spin-X 0.22 µm cellulose acetate filters. Ultrafiltration was carried out in vivaspin 500 polyethersulfone (PES) membrane concentrators with a molecular weight cut-off (MWCO) of 10 kDa or 5 kDa. Centrifugation was carried out on an eppendorf 5415R fixed angle rotor centrifuge operating at 14000 rcf at 20 °C or in an eppendorf 5810 swing-bucket rotor centrifuge operating at 3220 rcf at 20 °C.

Trastuzumab is a chimeric IgG1 full length antibody directed against HER2. The antibody was obtained in its clinical formulation (Roche, lyophilised), dissolved in 10 ml sterile water and then buffer exchanged completely for borate buffer pH 8.0 via ultrafiltration (MWCO 10 kDa, Amicon). Concentration was determined by UV-vis absorbance (using $\varepsilon_{280} = 215380$ M$^{-1}$ cm$^{-1}$ for trastuzumab mAb), adjusted to 40 µM (5.88 mg/mL) and was stored in flash frozen aliquots at −20 °C. For experiments, aliquots were thawed and used immediately. The following acronyms are used to describe antibody fragments based on their constituent heavy and light chains: heavy-heavy-light (HHL), heavy-heavy (HH), heavy-light (HL, a.k.a. half antibody), heavy (H) and light (L) chains.
Analytical methods for antibody-drug conjugates

SDS-PAGE

Non-reducing glycine-SDS-PAGE 12% acrylamide gels were performed following standard lab procedures. A 4% stacking gel was used and a broad-range MW marker (10–250 kDa, BioLabs) was co-run to estimate protein weights. Samples (3 μL at ~35 μM in total trastuzumab) were quenched with maleimide (1 μL of a 10 mM solution in PBS, >110 eq.) and mixed with loading buffer (2 μL, composition for 6x SDS: 1 g SDS, 3 mL glycerol, 6 mL 0.5 M Tris buffer pH 6.8, 2 mg R-250 dye) and heated at 65 °C for 2 minutes. For reducing gel (using β-mercaptoethanol (BME) as reducing agent), samples (3 μL at ~35 μM in total trastuzumab) were mixed with loading buffer (2 μL, composition for 4 x SDS: 0.8 mL BME, 0.8 g SDS, 4 mL glycerol, 2.5 mL 0.5 M Tris buffer pH 6.8, 2.5 mL H2O, 2 mg R-250 dye). The gel was run at constant current (30-35 mA) for 40 min in 1x SDS running buffer. All gels were stained following a modified literature protocol where 0.12 % of Coomassie G-250 and Coomassie R-250 dyes were added to the staining solution (5:4:1 MeOH:H2O:AcOH).

Determination of concentrations for trastuzumab NGM and PD ADCs

UV-vis spectra were recorded on a Varian Cary 100 Bio UV-visible spectrophotometer, operating at 20 °C. Sample buffer was used as blank for baseline correction. Calculation of antibody fragment concentration followed the Beer-Lambert law using $\varepsilon_{280} = 215380 \text{ M}^{-1} \text{ cm}^{-1}$ for trastuzumab. Concentrations of trastuzumab NGM-MMAE and Mal-MMAE conjugates 1 and 2 were calculated using the same extinction coefficient for trastuzumab since the maleamic acid and succinimide groups and MMAE were found to have negligible absorption at 280 nm compared to trastuzumab. Concentrations of trastuzumab PD-MMAE conjugates 3 and 4 were calculated using the same extinction coefficient, applied to a corrected absorption value at 280 nm calculated as follows by subtracting pyridazinedione absorption at 340 nm using 0.28 as a correction factor. $A_{280}$ is measured absorption at 280 nm and $A_{340}$ is pyridazinedione absorption at 340 nm.

$$[\text{NGM-MMAE ADC}] = \frac{A_{280}}{l \times \varepsilon_{280}} \quad [\text{PD-MMAE ADC}] = \frac{A_{280} - (0.28 \times A_{340})}{l \times \varepsilon_{280}}$$
**Liquid chromatography mass spectrometry (LC-MS)**

Trastuzumab and PD-MMAE ADC samples were prepared (50 µL of 7.5 µM solution in BBS) and deglycosylated by addition of PNGase F (Glycerol-free) (1.25 µL, 625 units; New England BioLabs) and incubation at 37 °C for 16 h. The samples were then buffer exchanged and concentrated by ultrafiltration into water (16 µM, 2.4 mg/mL). LC-MS analysis was performed on a Hypersil Gold C4 1.9 µm 2.1 × 50 mm column connected to an Agilent 1100 HPLC connected to a Micromass Q-TOF API-US. Detection wavelength was 254 nm. Samples were eluted with 95:5 Water:MeCN (0.1% formic acid) to 5:95 Water: MeCN (0.1% formic acid) gradient over 7 min with a flow rate of 0.4 mL/min. MS Mode: ES+. Scan Range: m/z = 500-4000. Scan time: 1.0 s. Data was obtained in continuum mode. The electrospray source of the MS was operated with a capillary voltage of 3 kV and a cone voltage of 25 V. Nitrogen was used as the nebulizer and desolvation gases at a total flow of 756 L/h. Ion series were generated by integration of the total ion chromatogram (TIC) over the 3.0-4.5 min range. Total mass spectra for protein samples were reconstructed from the ion series using MassLynx V4.0 SP4 software.

**Hydrophobic interaction chromatography (HIC)**

Samples of trastuzumab and ADCs (~35 µM) were diluted 1:1 with water and injected (6-12 µL) onto a TSK-Gel Butyl-NPR 4.6 mm x 35 mm, 2.5 µm particle size column from Tosoh Bioscience, connected to an Agilent 1100 HPLC equipped with a diode array for UV-vis detection. Samples were run with a gradient from 100% buffer A (1.5 M ammonium sulfate, 25 mM sodium phosphates, pH 7) to 60% buffer B (25 mM sodium phosphates, 25% isopropanol (v/v), pH 7) over 52 minutes at a flow rate of 0.6 mL/min. The temperature was maintained at 20 °C for the duration of the run. Detection was by UV-vis absorbance at 280 nm. Drug-to-antibody ratio (DAR) species were assigned based on reference to the observed retention times for elution of DAR species 0, 2, 4 and 6 with increasing % of buffer B over time for Mal-MMAE ADC 2. Average DAR for each ADC was calculated as follows, where DARₙ corresponds to the peak area for a given DAR species with n being the number of MMAE drugs per antibody for that given DAR species.

\[
\text{Average DAR} = \frac{(\text{DAR}_1 + 2 \times \text{DAR}_2 + 3 \times \text{DAR}_3 + 4 \times \text{DAR}_4 + 5 \times \text{DAR}_5)}{\text{DAR}_0 + \text{DAR}_1 + \text{DAR}_2 + \text{DAR}_3 + \text{DAR}_4 + \text{DAR}_5}
\]
Size-exclusion chromatography (SEC)
Trastuzumab and ADCs were prepared as 20 μM (2.94 mg/mL) solutions in PBS. Samples were analysed by SEC-HPLC on a TSK gel G3000SWXL (7.8 mm x 30 cm) column connected to an Agilent 1100 HPLC system equipped with a 1100 series diode array detector. Samples were eluted using PBS 100 mM NaCl, 50 mM sodium phosphates and 0.02% sodium azide at pH 7.0 as mobile phase at a flow rate of 0.5 mL/ min. over 30 min. Detection wavelength was 280 nm.

Enzyme-linked immunosorbent assay (ELISA)
Binding affinity to HER2 receptor was determined by ELISA. PBS 140 mM sodium chloride and 12 mM sodium phosphates at pH 7.4 was used for all solutions. A maxisorp 96-well plate was coated for 2 h at 20 °C with HER2 (100 μL of a 0.25 μg/mL solution in PBS). One row of wells was coated with PBS only as a negative control. Next, each well was washed with PBS and blocked with a 3% BSA solution in PBS (200 μL) overnight at 4 °C. Then, the wells were washed with 0.1% Tween 20 in PBS, followed by PBS. Trastuzumab and ADCs were diluted in PBS yielding concentrations covering the range 30-0.12 nM. The dilution series was added, including PBS only and trastuzumab or ADC at the highest concentration in the absence of HER2 as negative controls. The plate was incubated for 2 h at 20 °C. Then, wells were washed and the detection antibody (100 μL of anti-human IgG, Fab-specific-HRP solution, 1:5000 in PBS) was added followed by incubation for 1 h at 20 °C. After another washing step, freshly prepared OPD solution (100 μL of 10 mg/20 mL OPD in phosphate-citrate buffer) was added to each well and the reaction was stopped by addition of 4 M HCl (50 μL). The colorimetric reaction was measured at 490 nm. Absorption values for a given concentration of trastuzumab or ADC were corrected as follows, where $A_{490_{corr}}$ is corrected absorption, $A_{490}$ is measured absorption, $A_{PBS}$ is absorption for PBS control, $A_{mAb30}$ is absorption for trastuzumab or ADC control at 30 nM and C is the given concentration for the respective data point.

$$A_{490_{corr}} = A_{490} - \left( \frac{A_{PBS} + A_{mAb30} \times C_{30}}{2} \right)$$
Alexa Fluor 488® conjugate serum stability

Alexa Fluor 488® trastuzumab fluorophore conjugates AFC 5 and AFC 12 were prepared as 0.2 mg/mL solutions in PBS 140 mM sodium chloride 12 mM sodium phosphates and 2 mM sodium azide at pH 7.4. The conjugates were diluted with 50% of human blood serum to give a final a concentration of 0.1 mg/mL of 5 or 12 and 1 mM of sodium azide. One aliquot (50 μL) for each conjugate was taken, flash frozen and stored at −80 °C. The remaining solution was incubated at 37 °C under mild shaking (300 rpm) and covered from light. Aliquots (50 μL) were taken at 1, 2, 4 and 7 days, flash frozen and stored at −80 °C. Aliquots were thawed, spin-filtered (0.22 μm filter) and diluted 100x with elution buffer. Samples (20 μL) of diluted aliquots were analysed by SEC-HPLC on a TSK gel G3000SWXL (7.8 mm x 30 cm) column connected to an Agilent 1200 HPLC system equipped with a 1200 series diode array detector and a fluorescence detector. Samples were eluted using PBS 140 mM NaCl, 100 mM sodium phosphates and 0.02% sodium azide at pH 7.0 as mobile phase at a flow rate of 0.5 mL/ min. over 30 min. Fluorescence was detected with an excitation wavelength of 495 nm and emission wavelength of 525 nm.

Determination of fluorophore to antibody ratio (FAR)

UV-vis spectra were recorded on a Varian Cary 100 Bio UV-visible spectrophotometer, operating at 20 °C. Sample buffer was used as blank for baseline correction. Calculation of fluorophore to antibody ratio (FAR) follows the formula below, with $\varepsilon_{280} = 215380 \text{ M}^{-1} \text{ cm}^{-1}$ for trastuzumab, $\varepsilon_{495} = 71000 \text{ M}^{-1} \text{ cm}^{-1}$ for Alexa Fluor 488®, 0.11 x Abs$_{495}$ as a correction factor for the dye absorption at 280 nm and 0.28 x Abs$_{340}$ as a correction factor for PD absorption at 280 nm.

$$\text{FAR} = \frac{(A_{495})/\varepsilon_{495}}{(A_{280}-0.11\times A_{495}-0.28\times A_{340})/\varepsilon_{280}}$$

$$[\text{PD– fluorophore conjugate}] = \frac{A_{280}-(0.11\times A_{AF495}+0.28\times A_{340})}{l\times \varepsilon_{280}}$$

Cell Lines

Human breast cancer cell lines HCC-1954 (Her-2-positive) and MCF-7 (Her-2-negative) were purchased from ATCC, and maintained in RPMI-1640, and DMEM medium, respectively, all
supplemented with 10% foetal bovine serum (Life Technologies, UK) at 37 °C, under humidified atmosphere containing 5% CO₂.

**In Vitro Cytotoxicity Assessment**

*In vitro* cytotoxicity of the compounds was evaluated in both human breast cancer cell lines (HCC-1954 and MCF-7) by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colourimetric assay. Briefly, 5×10⁴ cells were seeded in 96-well plates and incubated overnight. Cells were then exposed to a range of concentrations (0-100 nM) of MMAE (24h), trastuzumab (72h) and ADCs 1, 3 and 4 (72h). Following each treatment, cells were washed with PBS and incubated with drug-free medium for five days. The MTT reagent (5 mg/ml) was then added to each well and cells were incubated for 2h, followed by the addition of ethanol:DMSO (1:1) solution and optical density (OD) was measured at 540 nm. The percentage of viable cells was calculated as follows.

\[
\text{Cell viability (\%)} = \left( \frac{\text{OD}_{\text{treated cells}}}{\text{OD}_{\text{untreated cells}}} \right) \times 100
\]

**In Vivo Efficacy Assessment**

Female NSG mice (age, 6–8 wk; weight, 20–25 g) were sourced from our breeding colony at the Biological Services Unit (University College London). Animal experiments were performed in accordance with the U.K. Home Office Animals Scientific Procedures Act 1986 and United Kingdom Co-ordinating Committee on Cancer Research Guidelines for the Welfare and Use of Animals in Cancer Research² and approved by the University College London Animal Welfare and Ethical Review Body under project license 70-309.

Subcutaneous xenografts were established with the HCC-1954 cell line. Briefly, 2 × 10⁶ cells were injected into the right flank of mice and tumor volumes were caliper-measured and calculated using the formula volume = \(4\pi/3 \times (1/2 \times \text{length} \times 1/2 \times \text{width} \times 1/2 \times \text{height})\). Therapy was initiated when tumour volumes reached \(\sim 0.1 \text{ cm}^3\), approximately 14 days post tumour cell inoculation. Animals were then allocated to the following groups (n=8 per group): (1) Untreated; (2) Herceptin; (3) NGM-ADC-1; (4) PD-ADC 3; (5) PD-ADC 4. Each treatment was administered at a dose of 20 mg/kg 7qX3.

Tumour volumes were measured, and mouse weights monitored throughout the duration of the study. Mice were sacrificed if tumour volume reached 1.5 cm³ or if a weight loss of <10%
was incurred. In addition to weight loss, disease progression was also evaluated qualitatively by observation of behaviour and muscle wasting, as previously described.\textsuperscript{3,4} Tumour growth curves based on changes in tumour volume over time and survival were used to evaluate treatment efficacy.

**Statistical Analyses**

Data were plotted and analyzed using Prism software (version 6.0; GraphPad Software). Differences in tumour growth between the groups were assessed by 2-way ANOVA and multiple $t$ tests. Kaplan–Meier survival plots were analyzed using the log-rank test. Results were considered statistically significant at a $P$ value of 0.05 or less.
Conjugation protocols

Figure S1 – Reagents used for conjugation.
Conjugation of trastuzumab with NGM-MMAE 6 (NGM-MMAE ADC 1)

This conjugation was adapted from a previously described protocol. To trastuzumab (40 μM, 5 mL, 0.2 μmol) in BBS pH 8 was added TCEP (10 mM, 120 μL, 6 eq.) and the reaction was incubated at 37 °C for 2 h under mild agitation (400 rpm). Then, the reduced trastuzumab solution was cooled to 4 °C. Next, NGM-MMAE 6 was prepared in dry DMF (10 mM, 120 μL, 6 eq.), diluted with DMF (477 μL) and borate buffer pH 8 (1 mL) and immediately added to the reduced trastuzumab solution, thus giving a solution that was 10% (v/v) in DMF. The reaction was incubated at 4 °C for 30 min. Afterwards, excess reagents were removed by ultrafiltration (10 kDa MWCO) into BBS pH 8.4 and incubated at 20 °C over 72 h to effect hydrolysis of the maleimide unit to maleamic acid. Next, buffer swapped by ultrafiltration (10 kDa MWCO) into PBS to afford the modified trastuzumab NGM-MMAE ADC 1 in PBS. Yield 92%, average DAR by HIC 3.8.

Conjugation of trastuzumab with Mal-MMAE 7 (Mal-MMAE ADC 2)

This conjugation was adapted from a previously described protocol. To trastuzumab (40 μM, 3 mL, 0.12 μmol) in BBS pH 8 was added TCEP (10 mM, 24 μL, 2 eq.) and the reaction was incubated at 37 °C for 3 h under mild agitation (400 rpm). Next, Mal-MMAE 7 was prepared in dry DMF (10 mM, 96 μL, 8 eq.), diluted with DMF (240 μL) and immediately added to the reduced trastuzumab solution, thus giving a solution that was 10% (v/v) in DMF. The reaction was incubated at 37 °C for 45 min under mild agitation. Afterwards, excess reagents were removed by ultrafiltration (10 kDa MWCO) into PBS to afford the modified trastuzumab Mal-MMAE ADC 2 in PBS. Yield 91%, average DAR by HIC 2.9.

Conjugation of trastuzumab with PD-MMAE 8 (PD-MMAE ADC 3)

To trastuzumab (40 μM, 3 mL, 0.12 μmol) in BBS pH 8 was added TCEP (10 mM, 72 μL, 6 eq.) and the reaction was incubated at 37 °C for 2 h under mild agitation (400 rpm). Then, the reduced trastuzumab solution was cooled to 4 °C. Next, PD-MMAE 8 was prepared in dry DMF (10 mM, 96 μL, 8 eq.), diluted with DMF (360 μL) and borate buffer pH 8 (720 μL) and cooled to 4 °C before addition to the reduced trastuzumab solution, thus giving a solution that was 10% (v/v) in DMF. The reaction was incubated at 4 °C for 16 h. Afterwards, excess reagents were removed by ultrafiltration (10 kDa MWCO) into PBS to afford the modified trastuzumab PD-MMAE ADC 3 in PBS. Yield 86%, average DAR by HIC 4.0.
Conjugation of trastuzumab with PD-MMAE 9 (PD-MMAE ADC 4)
To trastuzumab (40 μM, 3 mL, 0.12 μmol) in BBS pH 8 was added TCEP (10 mM, 72 μL, 6 eq.) and the reaction was incubated at 37 °C for 2 h under mild agitation (400 rpm). Then, the reduced trastuzumab solution was cooled to 4 °C. Next, PD-MMAE 9 was prepared in dry DMF (10 mM, 240 μL, 20 eq.), diluted with DMF (60 μL) and cooled to 4 °C before addition to the reduced trastuzumab solution, thus giving a solution that was 10% (v/v) in DMF. The reaction was incubated at 4 °C for 16 h. Afterwards, excess reagents were removed by ultrafiltration (10 kDa MWCO) into PBS to afford the modified trastuzumab PD-MMAE ADC 4 in PBS. Yield 97%, average DAR by HIC 3.9.

Conjugation of trastuzumab with PD-propargylamide 10, followed by copper-catalysed Huisgen 1,3-dipolar cycloaddition (CuAAC) with Alexa Fluor 488® (conjugate AFC 5)
To trastuzumab (40 μM, 100 μL, 0.004 μmol) in BBS pH 8 was added TCEP (10 mM, 2.4 μL, 6 eq.) and the reaction was incubated at 37 °C for 2 h under mild agitation (400 rpm). Then, the reduced trastuzumab solution was cooled to 4 °C. Next, PD-propargylamide 10 was prepared in dry DMF (10 mM, 8 μL, 20 eq.), diluted with DMF (4 μL) and cooled to 4 °C before addition to the reduced trastuzumab solution, thus giving a solution that was 10% (v/v) in DMF. The reaction was incubated at 4 °C for 16 h. Afterwards, excess reagents were removed by ultrafiltration (10 kDa MWCO) into 50 mM phosphate buffer at pH 7.0 to afford the modified trastuzumab PD-propargylamide conjugate. Next, to this conjugate (40 μM, 70 μL, 0.0028 μmol) was added tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, 50 mM, 1.68 μL 30 eq.) and CuSO₄ (20 mM, 0.84 μL, 6 eq.). Then, added Alexa Fluor 488® in DMF (5 mM, 5.6 μL, 10 eq.), followed by sodium ascorbate (final concentration 5 mM) and the reaction mixture was incubated at 37 °C for 5 h. Excess reagents were removed by desalting, using a PD MiniTrap G-25 filter (GE Healthcare Life Sciences) eluting with PBS pH 7.4 (10 mM EDTA) followed by ultrafiltration (10 kDa MWCO) into fresh PBS to afford the modified trastuzumab conjugate AFC 5 with 94% yield and a fluorophore to trastuzumab ratio of 3.1.

Conjugation of trastuzumab with Mal-propargylamide 11, followed by copper-catalysed Huisgen 1,3-dipolar cycloaddition (CuAAC) with Alexa Fluor 488® (conjugate AFC 12)
To trastuzumab (40 μM, 300 μL, 0.012 μmol) in BBS pH 8 was added TCEP (10 mM, 2.4 μL, 2 eq.) and the reaction was incubated at 37 °C for 3 h under mild agitation (400 rpm). Then,
Mal-propargylamide 11 was prepared in dry DMF (10 mM, 9.6 μL, 8 eq.) and added to the reduced trastuzumab solution. The reaction was incubated at 20 °C for 45 min. Afterwards, excess reagents were removed by ultrafiltration (5 kDa MWCO) into 50 mM phosphate buffer at pH 7.0 to afford the modified trastuzumab Mal-propargylamide conjugate. Next, added tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, 25 mM, 9.6 μL 40 eq.) and CuSO₄ (10 mM, 6.8 μL, 8 eq.). Then, added Alexa Fluor 488® in DMF (5 mM, 24 μL, 10 eq.), followed by sodium ascorbate (final concentration 5 mM) and the reaction mixture was incubated at 20 °C for 1 h. Excess reagents were removed by ultrafiltration (5 kDa MWCO) into fresh PBS to afford the modified trastuzumab conjugate AFC 12 with 71% yield and a fluorophore to trastuzumab ratio of 2.6.

Conjugation of albumin with Mal-propargylamide 11, followed by copper-catalysed Huisgen 1,3-dipolar cycloaddition (CuAAC) with Alexa Fluor 488® (used as control for serum stability study)

To albumin (40 μM, 300 μL, 0.012 μmol) in BBS pH 8 was added dithiothreitol (DTT 10 mM, 6 μL, 5 eq.) and the reaction was incubated at 20 °C for 90 min. under mild agitation (400 rpm). The buffer was exchanged to fresh BBS pH 8 by ultrafiltration (5 kDa MWCO) to remove unreacted DTT and the volume was corrected to 300 μL. In a separate vial, Mal-propargylamide 11 was prepared in dry DMF (10 mM, 6 μL, 5 eq.) and added tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, 50 mM, 2.4 μL, 10 eq.) and CuSO₄ (20 mM, 6 μL, 10 eq.). Next, added Alexa Fluor 488® in DMF (5 mM, 18 μL, 7.5 eq.), followed by sodium ascorbate (final concentration 5 mM) in 50 mM phosphate buffer pH 7. This reaction mixture was incubated at 20 °C for 4 h. Then, it was added to the reduced albumin solution and the mixture was incubated at 20 °C for 1 h. Afterwards, excess reagents were removed by ultrafiltration (5 kDa MWCO) with 50 mM phosphate buffer at pH 7.0 and the volume corrected to 300 μL to afford the modified albumin conjugate in PBS with 73% yield and a fluorophore to albumin ratio of 0.9.
**Supplementary figures and tables**

**Figure S2** – LC-MS data of unmodified trastuzumab

**Figure S2** – ESI-MS data for unmodified trastuzumab. A) non-deconvoluted ion series and B) deconvoluted ion series mass spectra. Trastuzumab observed mass of 145176 Da.
Figure S3 – LC-MS data of PD-MMAE ADC 3

**Figure S3** – ESI-MS data for PD-MMAE ADC 3. A) non-deconvoluted ion series and B) deconvoluted ion series mass spectra. Observed mass of 151106 Da (calculated 151099 Da).
Figure S4 – LC-MS data of PD-MMAE ADC 4.

Figure S4 – ESI-MS data for PD-MMAE ADC 4. A) non-deconvoluted ion series and B) deconvoluted ion series mass spectra. PD-MMAE ADC 4 observed mass of 152733 Da (calculated 152717 Da).
Figure S5 – SEC-HPLC chromatograms of trastuzumab, NGM-MMAE ADC XX and Mal-MMAE ADC XX.

A  Unmodified trastuzumab

B  NGM-MMAE ADC 1
C  Mal-MMAE  99%

D  PD-MMAE ADC 3

3%  97%
Figure S5 – SEC-HPLC chromatograms with peak percentages of monomeric (rt 15.8-16.2 min) and aggregate (rt 13.6-13.7 min) species for A) unmodified trastuzumab, B) NGM-MMAE ADC 1, C) Mal-MMAE ADC 2, C) PD-MMAE ADC 3, and E) PD-MMAE ADC 4.

Figure S6 – HER2 ELISA of PD-MMAE ADC 3 & 4 compared with trastuzumab

Figure S6 – Binding activity to HER2 of PD-MMAE ADC 3 & 4 compared with trastuzumab by ELISA assay.
Figure S7 – SEC-HPLC chromatograms of serum stability study with AFC 5 and AFC 12

**Figure S7** – SEC-HPLC with fluorescence detection (excitation 495 nm, emission 525 nm) chromatograms of antibody-fluorophore conjugates A) AFC 12, and B) AFC 5, incubated in blood serum for 7 days and analysed on days 0, 1, 2, 4 and 7. Transfer of fluorophore can be seen over 7 days for the classical maleimide conjugate (AFC 12) whereas a significant reduction in transfer is seen for the PD conjugate (AFC 5).
Synthesis General Remarks

All reactions were carried out at atmospheric pressure with stirring at 20 °C unless otherwise stated. Reagents and solvents were purchased from Sigma Aldrich and Alfa Aesar and used as supplied. H₂N-PEG₁₂-CH₂CH₂CO₂ᵗBu and BocHN-vc-PABC-PNP were purchased from Iris Biotech GmbH. Reactions were monitored by TLC analysis carried out on silica gel SIL G/UV254 coated onto aluminium plates purchased from VWR. Visualization was carried out under a UV lamp operating at 254 nm wavelength and by staining with a solution of phosphomolybdic acid in ethanol (12 g/250 mL), followed by heating. Flash column chromatography was carried out on silica gel 60 (0.04-0.063 mm, 230-400 mesh) purchased from Merck. Preparative thin-layer chromatography (PTLC) was carried out on 20×20 cm glass plates coated with PLC silica gel 60 F₂₅₄ (2 mm) purchased from Merck. Chromatographic and crystallisation purifications used solvents dichloromethane (DCM), methanol (MeOH), ethyl acetate (EtOAc) and petroleum ether 40 °C - 60 °C boiling range, purchased from Sigma Aldrich. Nuclear magnetic resonance spectra were recorded in either CDCl₃ or MeOD-d₄ (unless another solvent is stated) on Bruker NMR spectrometers operating at ambient 20 °C probe. ¹H spectra were recorded at 400, 500 or 600 MHz and ¹³C spectra were recorded at 100, 125 or 150 MHz, using residual solvents as internal reference. Where necessary, DEPT135, COSY, HMQC, HMBC and NOESY spectra have been used to ascertain structure. Data is presented as follows for ¹H: chemical shift in ppm (multiplicity, J coupling constant in Hz, nº of H, assignment on structure); and on ¹³C: chemical shift in ppm (assignment on structure). Multiplicity is reported as follows: s (singlet), d (doublet), t (triplet), q (quartet), quint. (quintet), sext. (sextet), oct. (octet), m (multiplet), br (broad), dd (doublet of doublet). Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FTIR spectrometer operating in ATR mode. Melting points were measured on a Gallenkamp apparatus and are uncorrected. Experimental procedures for all isolated compounds are presented. All yields quoted are isolated yields, unless otherwise stated.
Synthesis of compounds

Synthesis of NGM-MMAE 6 has been previously described.²

Scheme S1 – Synthesis of Mal-MMAE 6.
Scheme S2 – Synthesis of PD-MMAE 9 and Mal-propargylamide 11.
Scheme S3 – Synthesis of PD-MMAE 8 and PD-propargylamide 10.
tert-butyl-46-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-41-oxo-
4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxa-40-azaheptacontanoate 14

Maleimide-C6-PEG12-tert-butyl ester 14

In a 10 mL round-bottom flask, oven dried, maleimide-N-hexanoic acid (11 mg, 53 µmol, 1.2 eq.), prepared as reported,6 HOBT hydrate (1.2 mg, 9 µmol, 0.2 eq) and HBTU (34 mg, 90 µmol, 2 eq.) were dissolved in DMF (0.5 mL). Then, added DIPEA (23 µL, 183 µmol, 3 eq.). The solution was stirred at 20 °C for 10 min. Next, added H2N-PEG12-CH2CH2CO2Bu (30 mg, 44 µmol, 1 eq.) in DMF (0.5 mL), followed by addition of DIPEA (23 µL, 183 µmol, 3 eq.). The solution was stirred at 20 °C for 16 h. Then, concentrated under vacuum, added DCM (10 mL) and washed with 15% aq. citric acid (10 mL), aq. sat. NaHCO3 (10 mL) and 40% aq. LiCl (2×10 mL). The organic layer was dried (MgSO4), filtered and concentrated under vacuum to yield a pale yellow oil which was purified by flash chromatography on silica with DCM:EtOAc:MeOH (15:5:1 to 15:5:2 v/v) to afford the title compound as a colourless oil (11 mg, 13 µmol, 29%). Characterisation data: FTIR νmax (cm⁻¹) 2866, 1704, 1668, 1365, 1248, 1095, 947, 832, 695. 1H NMR (400 MHz, CDCl3) 1.23-1.35 (quint., J = 7.6 Hz, 2H, CH₂), 1.44 (s, 9H, CH₃), 1.54-1.62 (overlapped quint., J = 7.6 Hz, 4H, CH₂), 2.14-2.17 (t, J = 7.6 Hz, 2H, CH₂), 2.48-2.51 (t, J = 6.4 Hz, 2H, CH₂), 3.40-3.46 (t, J = 5.2 Hz, 2H, CH₂), 3.47-3.52 (t, J = 7.6 Hz, 2H, CH₂), 3.52-3.56 (t, J = 5.2 Hz, 2H, OC₂H₅), 3.57-3.67 (overlapped multiplets, 44H, OC₂H₅), 3.68-3.72 (t, J = 6.4 Hz, 2H, OCH₂), 6.25-6.32 (br, 1H, NH), 6.70 (s, 2H, CH); 13C NMR (100 MHz, CDCl3) 25.2 (CH₂), 26.5 (CH₂), 28.2 (CH₃), 28.4 (CH₂), 36.4 (CH₂), 36.5 (CH₂), 37.8 (CH₂), 39.2 (CH₂), 67.0 (CH₂, PEG), 70.1 (CH₂, PEG), 70.3 (CH₂, PEG), 70.5 (CH₂, PEG), 70.6-70.8 (overlapped CH₂, PEG), 80.6 (C), 134.1 (C), 170.9 (CO), 171.0 (CO), 172.8 (CO). LRMS (ESI+) 889 (100, [M+Na]+), 867 (50, [M+H]+); HRMS (ESI+) calcd. for C₄₁H₇₅N₂O₁₇ [M+H]+ 867.5066, observed: 867.5069.
In a 10 mL round-bottom flask, maleimide-C6-PEG_{12}-tert-butyl ester 14 (10 mg, 12 µmol, 1.3 eq.) was dissolved in DCM (0.5 mL). Then, added trifluoroacetic acid (0.5 mL, 6.4 mmol). The solution was stirred at 20 °C for 5 h. Then, concentrated under vacuum, redissolved in DCM (10 mL) and washed with 10 mM aq. HCl (10 mL). The organic layer was dried (MgSO\textsubscript{4}), filtered and concentrated under vacuum to afford a colourless oil. Dissolved the Maleimide-C6-PEG\textsubscript{12}-CO\textsubscript{2}H thus formed in DMF (0.5 mL) and added HOBt hydrate (0.2 mg, 1.5 µmol, 0.2 eq.) and HBTU (9.1 mg, 24 µmol, 2.7 eq.). Then, added DIPEA (4.7 µL, 27 µmol, 3 eq.). The solution was stirred at 20 °C for 10 min. Next, added MMAE (6.4 mg, 8.9 µmol, 1 eq.) in DMF (0.5 mL), followed by DIPEA (4.7 µL, 27 µmol, 3 eq.). The solution was stirred at 20 °C for 16 h. Then, concentrated under vacuum, added DCM (10 mL) and washed with 15% aq. citric acid (10 mL), aq. sat. NaHCO\textsubscript{3} (10 mL) and 40% aq. LiCl (2×10 mL). The organic layer was dried (MgSO\textsubscript{4}), filtered and concentrated under vacuum to yield a pale yellow oil which was purified by flash chromatography on silica with a gradient from DCM:EtOAc:MeOH (5:5:1 v/v) to DCM:MeOH (10:1 v/v) to afford the title compound as a colourless oil (12.1 mg, 8 µmol, 90%). Characterisation data: \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}) 0.72-0.78 (dd, \( J = 6.4, 6H, \text{MMAE} \)), 0.78-0.87 (m, 6H, \text{MMAE} \)), 0.87-0.92 (m, 3H, \text{MMAE} \)), 0.93-0.99 (m, 3H, \text{MMAE} \)), 1.15-1.34 (m, \text{MMAE} overlapped with \( CH\textsubscript{2} \)), 1.47-1.63 (overlapped quint., \( J = 7.6 \text{ Hz}, 4H, CH\textsubscript{2} \)), 1.71-1.88 (m, \text{MMAE} \)), 1.88-2.05 (m, \text{MMAE} \)), 2.06-2.11 (t, \( J = 7.6 \text{ Hz}, 2H, CH\textsubscript{2} \)), 2.12-2.23 (m, \text{MMAE} \)), 2.23-2.44 (m, \text{MMAE} \)), 2.48-2.71 (m, \text{MMAE} \)), 2.76-2.86 (m, \text{MMAE} \)), 2.88-2.97 (m, 4H, \text{MMAE} overlapped with \( CH\textsubscript{2} \)), 3.02-3.11 (m, \text{MMAE} \)), 3.21-3.27 (m, \text{MMAE} \)), 3.30-3.39 (m, \text{MMAE} overlapped with PEG \( CH\textsubscript{2} \)), 3.41-3.46 (t, \( J = 7.2 \text{ Hz }, 2H, CH\textsubscript{2} \)), 3.46-3.49 (t, \( J = 4.8 \text{ Hz }, 2H, \text{PEG OCH}\textsubscript{2} \)), 3.50-3.62 (m, \text{PEG OCH}\textsubscript{2} \)), 3.68-3.73 (t, \( J = 6.8 \text{ Hz }, 2H, \text{PEG OCH}\textsubscript{2} \)), 3.73-3.80 (m, \text{MMAE} \)), 3.93-4.02 (m, \text{MMAE} \)), 4.02-4.13 (m, \text{MMAE} \)), 4.13-4.24 (m, \text{MMAE} \)), 4.49-4.52 (d, \( J = 11.2 \text{ Hz }, 1H, \text{MMAE} \)), 4.54-4.60 (t, \( J = 8.4 \text{ Hz }, 1H, \text{MMAE} \)), 4.61-4.70 (m, \text{MMAE} \)), 4.75-5.00 (m, \text{MMAE} \)), 6.20-6.28 (br, 1H, \text{NH} \)), 6.40-6.53 (m, \text{MMAE} \)), 6.62 (s, 2H, \text{CH} \)), 7.16-7.34 (m, 5H, Ar\text{H} \text{MMAE}). \textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}) 11.1 (\text{CH}\textsubscript{3} \text{MMAE} \)), 14.0 (\text{CH}\textsubscript{3} \text{MMAE} \)), 14.8 (\text{CH}\textsubscript{3} \text{MMAE} \)), 16.0 (\text{CH}\textsubscript{3} \text{MMAE} \)), 18.6 (\text{CH}\textsubscript{3} \text{MMAE} \)), 19.5 (\text{CH}\textsubscript{3} \text{MMAE} \)), 25.1
(CH₂, MMAE), 25.1 (CH₂, MMAE), 25.2 (CH₂), 25.8 (CH₂, MMAE), 26.1 (CH₂, MMAE), 26.1 (CH₂), 28.5 (CH₂), 29.8 (MMAE), 30.8 (CH, MMAE), 31.1 (CH, MMAE), 33.6 (CH, MMAE), 34.2 (CH₂), 36.5 (CH₂, PEG), 37.8 (CH₂), 39.3 (CH₂, PEG), 45.1 (CH, MMAE), 47.9 (CH₂, MMAE), 51.8 (CH, MMAE), 54.1 (CH, MMAE), 58.1 (OCH₃, MMAE), 60.2 (CH, MMAE), 61.1 (OCH₃, MMAE), 62.3 (MMAE), 67.5 (overlapped CH₂ and OCH, PEG and MMAE), 70.1 (CH₂, PEG), 70.3 (CH₂, PEG), 70.5-70.8 (overlapped CH₂, PEG), 75.9 (CH, MMAE), 78.7 (CH, MMAE), 82.1 (CH, MMAE), 126.5 (ArCH, MMAE), 127.4 (ArCH, MMAE), 128.2 (ArCH, MMAE), 134.2 (C), 141.3 (MMAE), 169.9 (CO), 170.7 (CO), 171.0 (CO), 172.2 (CO), 172.9 (CO), 174.8 (CO). LRMS (ESI+) 1532 (100, [M+Na]+), 1510 (15, [M+H]+); HRMS (ESI+) calcd. for C₇₆H₁₃₂N₇O₂₃ [M+H]+ 1510.9375, observed: 1510.9379.
In a 10 mL round-bottom flask, maleic anhydride (196 mg, 2 mmol) and glycine (150 mg, 2 mmol, 1 eq.) were suspended in acetic acid (4 mL). The mixture was heated at 140 °C for 16 hours. Then, cooled down to 20 °C and concentrated in vacuum. Purified by column chromatography in silica with DCM:AcOH (95:5 v/v). Next, recrystallised by dissolving in refluxing DCM:hexanes (1:1 v/v), cooling down and keeping at 4 °C over 48 h to crystallise. Filtered and dried under vacuum to afford the title compound as a white solid (95 mg, 0.61 mmol, 31%). Characterisation data: m.p. 110-111 °C. FTIR $\nu_{\text{max}}$ (cm$^{-1}$) 3100-2600 (broad), 2940, 1704, 1431, 1258, 832, 689. $^1$H NMR (500 MHz, MeOD-d$_4$) 4.24-4.25 (s, 2H, CH$_2$), 6.92-6.93 (s, 2H, CH); $^{13}$C NMR (125 MHz, MeOD-d$_4$) 39.2 (CH$_2$), 135.7 (CH), 170.9 (CO), 171.7 (CO).
LRMS (NSI) 154 (100, [M−H]^−); HRMS (ESI) calcd. for C₆H₄NO₄ [M−H]^− 154.0146, observed: 154.0147.
This protocol is a modification of a literature protocol. In a 10 mL round-bottom flask, suspended BocHN-vc-PABC-PNP (31 mg, 48 µmol, 1.6 eq.), and 1-hydroxybenzotriazole hydrate (HOBt, 12 mg, 90 µmol, 3 eq.) in DMF (0.2 mL). Next, dissolved monomethyl auristatin E (MMAE, 25 mg, 30 µmol, 1 eq.) in MeCN (0.8 mL) and added to the reaction mixture. Then, added DIPEA (52 µL, 300 µmol, 10 eq.). The solution turned yellow over time. The solution was stirred at 20 °C over 16 hours. Then, added DCM (10 mL) and washed with aq. sat. NaHCO₃ (3×10 mL), 0.1 M aq. acetates pH 5 (10 mL) and 1:1 water:sat. LiCl (10 mL). The organic layer was dried (MgSO₄), filtered and concentrated under vacuum to yield an
off-white solid which was purified by preparative liquid chromatography on silica with a
gradient of DCM:EtOAc:MeOH (5:5:2 to 10:3:1 v/v) to afford the title compound as a white
solid (21 mg, 17 μmol, 57%). Characterisation data: $^1$H NMR (600 MHz, CDCl$_3$ and MeOD-d$_4$
mix) 0.77-0.87 (overlapped d, $J = 6.6$ Hz, 9H, CH$_3$ and MMAE), 0.87-0.91 (overlapped d, $J =
6.6$ Hz, 6H, CH$_3$ and MMAE), 0.91-0.97 (m, 5H, MMAE), 1.00-1.05 (m, 3H, MMAE), 1.10-1.20
(m, MMAE), 1.21-1.28 (m, MMAE), 1.28-1.36 (m, MMAE), 1.37-1.43 (s, 9H, CH$_3$ Boc), 1.46-
1.56 (m, $J = 6.6$ Hz, 2H, CH$_2$), 1.62-1.72 (m, 2H, CH$_2$ and MMAE), 1.75-1.82 (m, 1H, CH$_2$), 1.83-
2.00 (m, MMAE), 2.00-2.08 (m, $J = 6.6$ Hz, 3H, CH and MMAE), 2.10-2.23 (m, MMAE), 2.26-
2.60 (m, MMAE), 2.84-2.93 (m, MMAE), 2.97-3.04 (m, MMAE), 3.05-3.11 (m, 1H, CH), 3.12-
3.15 (br, MMAE), 3.16-3.24 (m, 1H, CH), 3.27-3.32 (m, MMAE), 3.34-3.37 (m, MMAE), 3.40-
3.50 (m, MMAE), 3.65-3.75 (m, MMAE), 3.80-3.85 (d, $J = 7.8$ Hz, 1H, MMAE), 3.86-3.91 (d, $J =
6.6$ Hz, 1H, CH), 3.95-4.22 (overlapped m and H$_2$O, MMAE), 4.45-4.55 (m, 1H, CH), 4.56-4.62
(t, $J = 8.4$ Hz, 1H, MMAE), 4.62-4.74 (overlapped m, MMAE and CH$_2$), 4.75-4.82 (d, $J = 3.6$ Hz,
1H, MMAE), 5.00-5.19 (overlapped m, 2H, BocNH and CH$_2$), 7.16-7.36 (overlapped m, 7H,
ArH MMAE and PABC), 7.53-7.56 (d, $J = 7.2$ Hz, 2H, ArH PABC). $^{13}$C NMR (150 MHz, CDCl$_3$ and
MeOD-d$_4$ mix) 10.5 (CH$_3$, MMAE), 13.8 (CH$_3$, MMAE), 14.0 (CH$_3$, MMAE), 15.6 (CH$_3$, MMAE),
17.6 (CH$_3$, MMAE), 18.3 (CH$_3$), 18.8 (CH$_3$), 19.0 (CH$_3$, MMAE), 24.6 (CH$_2$, MMAE), 24.7 (CH$_2$,
MMAE), 25.6 (CH$_2$, MMAE), 26.1 (CH$_2$), 28.0 (CH$_3$, Boc), 29.2 (CH, MMAE), 29.4 (CH$_2$), 29.5
(CH$_3$, MMAE), 30.1 (CH, MMAE), 30.8 (CH), 31.8 (CH, MMAE), 33.0 (CH, MMAE), 37.3 (CH$_2$,
MMAE), 38.9 (CH$_2$), 44.7 (CH, MMAE), 47.8 (CH$_2$, MMAE), 50.7 (CH, MMAE), 53.1 (CH,
MMAE), 54.3 (CH), 57.7 (OCH$_3$, MMAE), 59.7 (CH, MMAE), 60.1 (CH), 60.6, (OCH$_3$, MMAE),
61.4 (MMAE), 64.8 (CH$_2$), 67.2 (OCH, MMAE), 75.5 (OCH, MMAE), 78.3 (CH, MMAE), 80.0 (C,
Boc), 82.1 (OCH, MMAE), 85.6 (MMAE), 119.9 (ArCH), 126.2 (ArCH, MMAE), 127.2 (ArCH,
MMAE), 127.9 (ArCH, MMAE), 128.1 (ArC, MMAE), 128.4 (ArCH), 132.2 (ArC), 137.8 (ArC),
141.3 (ArC, MMAE), 156.4 (CO, Boc), 157.4 (CO), 160.4 (CO), 170.2 (CO, MMAE), 170.3 (CO),
170.4 (CO, MMAE), 172.8 (CO, MMAE), 173.3 (CO), 174.6 (CO, MMAE). LRMS (ESI) 1246 (100,
[M+Na]$^+$), 1224 (38, [M+H]$^+$); HRMS (ESI) calcd. for C$_{63}$H$_{102}$N$_{10}$O$_{14}$Na [M+Na]$^+$ 1245.7469,
observed: 1245.7451.
In a 10 mL round-bottom flask, BocHN-vc-PABC-PNP (129 mg, 0.2 mmol, 1 eq.) was dissolved in DMF (2 mL). Next, added HOBt hydrate (54 mg, 0.4 mmol, 2 eq.), followed by addition of propargylamine (13 µL, 0.2 mmol, 1 eq.) and DIPEA (104 µL, 0.6 mmol, 3 eq.). The solution was stirred at 20 °C for 8 h. Then, concentrated under vacuum, redissolved in MeOH and concentrated under vacuum again. Purified by flash chromatography on silica with a gradient of DCM:EtOAc:MeOH (10:3:1 to 10:3:2 v/v) to afford the title compound as an off-white solid (101 mg, 0.18 mmol, 90%). Characterisation data: no melting point starts to decompose at 196-198 °C. FTIR ν_max (cm⁻¹): 3297, 2957, 2927, 2870, 2422, 1694, 1669, 1634, 1607, 1405, 1165. ¹H NMR (500 MHz, MeOD-d4) 0.93-0.98 (overlapped d, J = 6.5 Hz, 6H, CH₃), 1.42-1.46 (s, 9H, CH₃), 1.50-1.65 (m, J = 7.0 Hz, 2H, CH₂), 1.70-1.80 (m, J = 9.5 Hz, 1H, CH₂), 1.85-1.95 (m, 1H, CH₂), 2.01-2.10 (oct., J = 7.0 Hz, 1H, CH), 2.56-2.57 (t, J = 2.5 Hz, 1H, CH), 3.06-3.14 (m, J = 7.0 Hz, 1H, CH₂), 3.16-3.25 (m, J = 7.0 Hz, 1H, CH₂), 3.86-3.88 (d, J = 2.5 Hz, 2H, CH₂), 3.90-3.93 (d, J = 7.0 Hz, 1H, CH), 4.50-4.53 (dd, J = 8.5 and 5.0 Hz, 1H, CH), 5.01-5.08 (br, 2H, CH₂), 7.30-7.32 (d, J = 8.5 Hz, 2H, ArH), 7.56-7.58 (d, J = 8.5 Hz, 2H, ArH); ¹³C NMR (125 MHz, MeOD-d4) 18.6 (CH₃), 19.8 (CH₃), 27.8 (CH₂), 28.7 (CH₃), 30.5 (CH₂), 31.0 (CH₂), 31.9 (CH), 40.2 (CH₂), 54.9 (CH), 61.7 (CH), 67.3 (CH₂), 72.0 (CH), 80.7 (C), 81.1 (C), 121.2 (ArCH), 129.6 (ArCH), 133.9 (ArC), 139.4 (ArC), 158.2 (CO), 158.5 (CO), 162.3 (CO), 172.3, (CO), 174.7 (CO). LRMS (NSI) 561 (100, [M+H]+), 583 (35, [M+Na]+); HRMS (NSI) calcd. for C₂₇H₄₃N₆O₇ [M+H]+ 561.3031, observed: 561.3024.
In a 10 mL round-bottom flask, dissolved BocHN-vc-PABC-MMAE 16 (34 mg, 28 µmol, 1 eq.) in dry DCM (0.9 mL) and added trifluoroacetic acid (TFA, 0.1 mL). Stirred at 20 °C over 2 hours. Next, concentrated under vacuum to dryness, redissolved in dry DCM, concentrated again, redissolved in dry MeCN and concentrated once more under vacuum. Dissolved the H$_2$N-vc-PABC-MMAE TFA salt in dry MeCN (2 mL) and added DIPEA (74 µL, 425 µmol, 15 eq.). In a separate flask, dissolved BocHN-PEG$_{12}$-CH$_2$CH$_2$CO$_2$H (20 mg, 28 µmol, 1 eq.) in dry MeCN (1 mL). Next, added (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (HBTU, 10.7 mg, 28 µmol, 1 eq.), HOBt hydrate (0.8 mg, 2.8 µmol, 0.1 eq.) and DIPEA (25 µL, 144 µmol, 5 eq.). The solution was stirred at 20 °C for 20 min. Then, added the H$_2$N-vc-PABC-MMAE solution with DIPEA previously prepared and stirred at 20 °C over 5 hours. Next, added DCM (20 mL) and washed with 15% aq. citric acid (10 mL), sat. aq. NaHCO$_3$ (10 mL) and water (10 mL). The organic layer was dried (MgSO$_4$), filtered and concentrated under vacuum to yield a colourless oil which was purified by preparative thin layer chromatography on silica with a gradient of DCM:EtOAc:MeOH (10:3:2 v/v) to DCM:MeOH (10:2 v/v) to afford the title compound as a colourless oil (29 mg, 16 µmol, 57%). Characterisation data: $^1$H NMR (600 MHz, CDCl$_3$ and MeOD-d$_4$ mix) 0.71-0.83 (overlapped m, 10H, CH$_3$ and MMAE), 0.83-0.86 (d, J = 6.6 Hz, 2H, MMAE), 0.87-0.93 (overlapped m, 9H, MMAE and CH$_3$), 0.94-0.98 (d, J = 6.6 Hz, 3H, MMAE), 1.10-1.19 (overlapped d, J = 6.6 Hz, 3H, MMAE), 1.19-1.21 (m, MMAE), 1.25-1.32 (m, MMAE), 1.34-1.41 (s, 9H, CH$_3$ Boc), 1.43-1.52 (m, J = 6.6 Hz, 2H, CH$_2$), 1.58-1.72 (m, 2H, CH$_2$ and MMAE), 1.73-1.81 (m, 1H, CH$_2$), 1.81-2.04 (m, MMAE), 2.04-2.11 (m, J = 6.6 Hz, 1H, CH and MMAE), 2.11-2.20 (m, MMAE), 2.25-2.33 (t, J = 7.2 Hz, 1H, MMAE), 2.35-2.58 (m, MMAE), 2.80-2.88 (m, MMAE), 2.94-2.99 (m, MMAE), 3.05-3.14 (overlapped m, 3H, CH and MMAE), 3.21-3.28 (m, PEG CH$_2$ and MMAE), 3.30-3.34 (m, MMAE), 3.44-3.48 (t, J = 5.4 Hz, 2H, PEG CH$_2$), 3.51-3.62 (overlapped m, PEG CH$_2$), 3.62-3.67 (m, 2H, PEG CH$_2$), 3.67-3.74 (m, MMAE), 3.77-3.82
(dd, $J = 8.4$ and $1.8$ Hz, 1H, MMAE), 3.94-4.03 (m, MMAE), 4.03-4.09 (m, 1H, MMAE), 4.09-4.13 (overlapped d and m, $J = 6.6$ Hz, 1H, CH and MMAE), 4.13-4.20 (m, 1H, MMAE), 4.44-4.52 (dd, $J = 9.6$ and $4.8$ Hz, 1H, CH), 4.52-4.62 (m, MMAE), 4.62-4.74 (overlapped m, MMAE and CH$_2$), 4.76-4.83 (d, $J = 3.6$ Hz, 1H, CH$_2$), 4.95-5.15 (overlapped m, 2H, BocNH and MMAE), 7.14-7.36 (overlapped m, 7H, Ar MMAE and PABC), 7.53-7.56 (d, $J = 8.4$ Hz, 2H, ArH PABC).

$^{13}$C NMR (150 MHz, CDCl$_3$ and MeOD-$d_4$ mix) 10.7 (C$_3$, MMAE), 13.9 (C$_3$, MMAE), 15.8 (CH$_3$, MMAE), 18.1 (CH$_3$, MMAE), 18.5 (CH$_3$), 19.0 (CH$_3$), 19.2 (CH$_3$, MMAE), 24.8 (CH$_2$, MMAE), 24.9 (CH$_2$, MMAE), 25.7 (CH$_2$, MMAE), 26.3 (CH$_2$), 28.4 (CH$_3$, Boc), 29.2 (CH$_2$), 29.6 (CH$_3$, MMAE), 30.3 (CH, MMAE), (CH$_2$), 30.8 (CH$_2$), 31.9 (CH, MMAE), 33.2 (CH, MMAE), 36.4 (CH$_2$, PEG), 37.6 (CH$_2$, MMAE), 38.9 (CH$_2$), 40.2 (CH$_2$, PEG), 43.7 (CH, MMAE), 47.9 (CH$_2$, MMAE), 50.9 (CH, MMAE), 53.2 (CH, MMAE), 53.3 (CH), 57.9 (OCH$_3$, MMAE), 59.5 (CH), 59.9 (OCH$_3$, MMAE), 60.9 (CH, MMAE), 64.9 (CH$_2$), 67.2 (OCH, MMAE), 67.3 (CH$_2$, PEG), 70.1 (CH$_2$, PEG), 70.1-70.5 (overlapped CH$_2$, PEG), 75.6 (OCH, MMAE), 78.5 (CH, MMAE), 79.4 (C, Boc), 82.2 (OCH, MMAE), 120.0 (ArCH), 126.3 (ArCH, MMAE), 127.3 (ArCH, MMAE), 128.1 (ArCH, MMAE), 128.3 (ArC, MMAE), 128.5 (ArCH), 132.2 (ArC), 138.0 (ArC), 141.3 (ArC, MMAE), 156.4 (CO, Boc), 157.5 (CO), 160.4 (CO), 170.2 (CO, MMAE), 170.4 (CO), 170.6 (CO, MMAE), 172.2 (CO), 172.9 (CO, MMAE), 173.4 (CO), 174.8 (CO, MMAE). LRMS (NSI) 589 (100, [M+NH$_4$+H]$^{2+}$), 1182 (10, [M+Na]$^+$); HRMS (NSI) calcd. for C$_{54}$H$_{92}$N$_7$O$_{20}$Na [M+Na]$^+$ 1182.6368, observed: 1182.6369.
In a 10 mL round-bottom flask, BocHN-vc-PABC-propargylamide 17 (210 mg, 0.37 mmol, 1 eq.) in dry DCM (1.8 mL) and added TFA (0.2 mL). Stirred at 20 °C over 2 hours. Next, concentrated under vacuum to dryness, redissolved in dry DCM, concentrated again, redissolved in dry MeCN and concentrated once more under vacuum. Dissolved H$_2$N-vc-PABC-propargylamide TFA salt in dry MeCN (4 mL) and added DIPEA (260 µL, 1.5 mmol, 4 eq.). In a separate flask, dissolved BocHN-PEG$_{12}$-CH$_2$CH$_2$-CO$_2$H (268 mg, 0.37 µmol, 1 eq.) in dry MeCN (4 mL). Next, added HBTU (142 mg, 0.37 mmol, 1 eq.), HOBt hydrate (5.0 mg, 37 µmol, 0.1 eq.) and DIPEA (130 µL, 0.75 mmol, 2 eq.). Stirred at 20 °C for 20 min. Then, added the H$_2$N-vc-PABC-propargylamide solution with DIPEA previously prepared and stirred at 20 °C over 16 hours. Next, added DCM (320 mL) and washed with 15% aq. citric acid (20 mL), sat. aq. NaHCO$_3$ (20 mL). Each aqueous layer was further extracted with DCM (2×40 mL). The combined organic layer was dried (MgSO$_4$), filtered and concentrated under vacuum to yield an oil which was purified by flash chromatography on silica with a gradient of DCM:EtOAc:MeOH (10:3:2 v/v) to DCM:MeOH (10:2 v/v) to afford the title compound as a light-brown oil (223 mg, 0.19 mmol, 51%). Characterisation data: FTIR $\nu_{\text{max}}$ (cm$^{-1}$): 3271, 2868, 1697, 1650, 1631, 1532, 1249, 1097. $^1$H NMR (500 MHz, MeOD-d$_4$ and CDC$_3$ mix) 0.96-0.99 (overlapped d, $J = 7.0$ Hz, 6H, CH$_3$), 1.41-1.47 (s, 9H, CH$_3$), 1.51-1.64 (m, $J = 7.0$ Hz, 2H, CH$_2$), 1.70-1.79 (m, $J = 9.0$ Hz, 1H, CH$_2$), 1.87-1.96 (m, 1H, CH$_2$), 2.06-2.17 (oct., $J = 7.0$ Hz, 1H, CH), 2.52-2.58 (t overlapped with m, $J = 6.0$ Hz, 3H, PEG CH$_2$ and CH), 3.08-3.14 (m, $J = 7.0$ Hz, 1H, CH$_2$), 3.16-3.20 (m, $J = 7.0$ Hz, 1H, CH$_2$), 3.20-3.24 (t, $J = 5.5$ Hz, 2H, PEG CH$_2$), 3.49-3.52 (t, $J = 6.0$ Hz, 2H, PEG CH$_2$), 3.58-3.65 (overlapped m, 44H, PEG CH$_2$), 3.72-3.78 (t, $J = 6.0$ Hz, 2H, PEG CH$_2$), 3.87-3.88 (d, $J = 2.5$ Hz, 2H, CH$_2$), 4.20-4.22 (d, $J = 7.0$ Hz, 1H, CH), 4.49-4.52 (dd, $J = 9.5$ and 5.0 Hz, 1H, CH), 5.01-5.08 (br, 2H, CH$_2$), 7.29-7.32 (d, $J = 8.5$ Hz, 2H, ArH), 7.58-7.60 (d, $J = 8.5$ Hz, 2H, ArH); $^{13}$C NMR (150 MHz, MeOD-d$_4$) 18.8 (CH$_3$), 19.8 (CH$_3$), 27.9 (CH$_2$), 28.8 (CH$_3$), 30.4(CH$_2$), 31.0 (CH$_2$), 31.8 (CH), 37.3 (CH$_2$, PEG), 40.1 (CH$_2$), 41.2 (CH$_2$)
PEG), 54.9 (CH), 60.5 (CH), 67.3 (\(CH_2\)), 68.2 (\(CH_2\), PEG), 71.1-71.5 (overlapped \(CH_2\), PEG), 72.1 (CH), 80.0 (C), 81.2 (C), 121.0 (ArCH), 129.7 (ArCH), 133.9 (ArC), 139.5 (ArC), 158.4 (CO), 162.2 (CO), 172.2, (CO), 173.8 (CO), 174.4 (CO). LRMS (NSI) 589 (100, \([M+NH_4+H]^+\)), 1183 (5, \([M+Na]^+\)); HRMS (NSI) calcd. for C_{54}H_{93}N_{7}O_{20}Na \([M+Na]^+\) 1182.6368, observed: 1182.6369.
To an oven-dried RBF was added a solution of diBrPD-Me/-Acid 20 (4.1 mg, 12 µmol) in dry THF (200 µL). The stirred solution was cooled to 4 °C with an ice/water bath before addition of DCC (2.47 mg, 12 µmol) and stirring continued at 4 °C for 10 min. Pentafluorophenol (1.26 µL, 12 µmol) was then added and the reaction mixture allowed to reach ambient temperature (≈20 °C) and stirred for 2 h. The reaction mixture was then filtered through a pipette with celite plug and solids washed with cold THF. The filtrate was concentrated in
vacuo then taken up in a minimum volume of cold THF and filtered again to ensure no precipitates remained. The PFP-activated ester was then dissolved in dry MeCN (200 µL).

To a solution of BocHN-vc-PABC-MMAE 16 (20 mg, 11 µmol) in CH₂Cl₂ (950 µL) was added TFA (50 µL, 654 µmol) and the reaction mixture stirred at 20 °C for 90 min. The mixture was concentrated in vacuo and re-suspended in CH₂Cl₂ (2 mL) repeatedly (5x) to evaporate any residual TFA. The remaining oil was dissolved in MeCN (500 µL), to which was added DIPEA (95 µL, 550 µmol (50 eq.)), and the mixture was added to the solution of PFP activated ester.

The reaction mixture was stirred at ambient temperature for 4 h before concentrating in vacuo. Purification of the oily residue by preparative TLC (CH₂Cl₂/EtOAc/MeOH 8:2:2) gave title compound 9 as a light brown oil (7 mg, 31%). Characterisation data: ¹H NMR (500 MHz, CDCl₃ and MeOD-d₄ mix) 0.75-0.90 (overlapped m, 12H, MMAE and Val CH₃), 0.94-1.02 (overlapped m, 12H, MMAE and Val CH₃), 1.22-1.24 (d, J = 7.45 Hz, 3H, MMAE CH₃), 1.50-1.58 (m, 2H, Cit CH₂), 1.65-1.76 (m, 2H, Cit CH₂), 1.78-1.84 (m, 2H, MMAE), 1.90-2.10 (m, 4H, MMAE), 2.15-2.25 (m, 3H, MMAE), 2.28-2.48 (m, 8H, MMAE), 2.50-2.64 (m, 3H, Cit CH₂ and CH), 2.85-2.90 (m, 3H, MMAE), 2.99 (m, 2H, MMAE), 3.14-3.24 (m, 2H), 3.27-3.33 (s overlapped with m, 3H, PEG CH₂ and MMAE), 3.38 (overlapped s, 3H, MMAE CH₃), 3.42-3.46 (m, 2H, MMAE), 3.51-3.56 (overlapped m, PEG CH₂), 3.60-3.70 (m, 47H, PEG CH₂ and PD NCH₃), 3.72-3.84 (m, MMAE), 3.94-4.06 (m, 2H, MMAE), 4.11-4.15 (m, 2H, MMAE), 4.21-4.28 (m, 2H, MMAE), 4.60-4.74 (overlapped m, MMAE and CH₂), 4.85 (s, 1H, PD NCH₂), 4.92 (d, J = 2.9 Hz, 1H, CH, MMAE), 5.01-5.16 (overlapped m, 3H), 5.86 (m, 1H, NH), 6.50-6.61 (m, 1H, NH), 7.21-7.37 (overlapped m, 7H, ArH MMAE and PABC), 7.49-7.59 (m, 1H, NH), 7.63-7.67 (d, J = 8.59 Hz, 2H, ArH PABC), 8.15 (m, 1H, NH), 9.09 (m, 1H, NH). ¹³C NMR (125 MHz, CDCl₃ and MeOD-d₄ mix) 11.0 (CH₃, MMAE), 14.0 (CH₃, MMAE), 14.5 (CH₃, MMAE), 18.3 (CH₃, MMAE), 18.7 (CH₃), 19.4 (CH₃), 19.5 (CH₃), 19.6 (CH₃, MMAE), 25.0 (CH₃, MMAE), 25.1 (CH₂, MMAE), 25.8 (CH₂, MMAE), 26.2 (CH₂), 27.2 (CH₂), 29.7 (CH₂), 30.2 (CH₃, MMAE), 30.3 (CH, MMAE), 33.5 (CH₂), 34.7 (NCH₃, PD), 36.9 (CH₂, PEG), 37.9 (CH₂, MMAE), 38.9 (CH, MMAE), 39.7 (CH₂NH, PEG), 39.9 (CH₂), 45.0 (CH, MMAE), 47.9 (CH₂, MMAE), 50.0 (NCH₂, PD), 51.6 (CH, MMAE), 53.5 (CH), 58.1 (OCH₃, MMAE), 59.8 (CH), 59.83 (OCH₃, MMAE), 60.1 (CH, MMAE), 61.0 (CH₂), 65.1 (CH, MMAE), 67.3 (OCH, MMAE), 67.4 (CH₂, PEG), 69.0 (CH₂), 69.7 (CH₂, PEG), 70.2-70.6 (overlapped CH₂, PEG), 75.9 (OCH, MMAE), 77.5 (CH, MMAE), 82.1 (OCH, MMAE), 120.0 (ArCH), 126.4 (ArCH, MMAE), 127.4 (ArCH, MMAE), 128.1 (ArCH, MMAE), 128.4 (ArC, MMAE), 128.6 (ArCH), 132.1 (ArC), 135.0 (CBr), 136.6 (CBr), 138.4 (ArC),
141.3 (ArC, MMAE), 152.5 (ArCO), 153.5 (ArCO), 157.4 (CO), 160.5 (CO), 165.8, 170.0 (CO, MMAE), 170.4 (CO), 170.5 (CO, MMAE), 172.1 (CO), 172.9 (CO, MMAE), 174.7 (CO, MMAE).
LRMS (NSI) 304 (100), 1032 (10, [M+H+Na]^2+); HRMS (NSI) calcd. for C_{92}H_{153}Br_{2}N_{13}O_{28} [M+2H]^2+ 1022.9652, observed: 1022.9646.
In a 10 mL round-bottom flask, dissolved Boc-HN-PEG$_{12}$-vc-PABC-propargylamide 19 (46 mg, 40 µmol, 1 eq.) in dry DCM (0.9 mL) and added TFA (0.1 mL). Stirred at 20 °C over 2 hours. Next, concentrated under vacuum to dryness, redissolved in dry DCM, concentrated again, redissolved in dry MeCN and concentrated once more under vacuum. Dissolved H$_2$N-PEG$_{12}$-valine-citruline-PABC-Alk TFA salt in dry MeCN (1 mL) and added DIPEA (35 µL, 200 µmol, 5 eq.). In a separate flask, dissolved 2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid (M-C2, 6.2 mg, 40 µmol, 1 eq.) in dry MeCN (1 mL). Next, added dicyclohexylcarbodiimide (DCC, 8.3 mg, 40 µmol, 1 eq.) and stirred at 20 °C for 10 min. Then, added pentafluorophenol (4.2 µL, 40 µmol, 1 eq.) and stirred at 20 °C for 15 min. Filtered this mixture through a short plug of cotton wool and added the filtrate to the H$_2$N-PEG$_{12}$-valine-citruline-PABC-Alk solution with DIPEA previously prepared. This solution was stirred at 20 °C over 4 hours. Next, concentrated under vacuum, redissolved in DCM (30 mL) and washed with 0.1 M sodium acetate buffer pH 5 (5 mL) and brine (5 mL). The organic layer was dried (MgSO$_4$), filtered and concentrated under vacuum, followed by purification by preparative thin layer chromatography on silica with DCM:MeOH (10:1 v/v) to afford the title compound as a beige solid (30 mg, 25 µmol, 62%). Characterisation data: no melting point, starts to decompose at 120-122 °C. FTIR ν$_{\text{max}}$ (cm$^{-1}$): 3293, 2869, 2412, 1713, 1684, 1652, 1626, 1444, 1091. $^1$H NMR (600 MHz, MeOD-d4 and CDCl$_3$ mix) 0.92-0.95 (overlapped d, J = 6.6 Hz, 6H, CH$_3$), 1.46-1.56 (m, J = 7.0 Hz, 2H, CH$_2$), 1.64-1.72 (m, J = 9.0 Hz, 1H, CH$_2$), 1.86-1.93 (m, J = 7.2 Hz, 1H, CH$_2$), 2.04-2.13 (oct., J = 6.5 Hz, 1H, CH), 2.30-2.32 (t, J = 2.4 Hz, 1H, CH), 2.51-2.53 (t, J = 6.6 Hz, 2H, PEG CH$_2$), 3.06-3.12 (m, J = 6.6 Hz, 1H, CH$_2$), 3.13-3.20 (m, J = 6.6 Hz, 1H, CH$_2$), 3.36-3.38 (t, J = 5.4 Hz, 2H, PEG CH$_2$), 3.51-3.53 (t, J = 5.4 Hz, 2H, PEG CH$_2$), 3.55-3.65 (overlapped m, PEG CH$_2$), 3.67-3.76 (m, J = 6.0 Hz, 2H, PEG CH$_2$), 3.87-3.89 (d, J = 2.4 Hz, 2H, CH$_2$), 4.15-4.16 (d, J = 7.2 Hz, 1H, CH), 4.16-4.17 (s, 2H, CH$_2$), 4.48-4.51 (dd, J = 9.0 and 4.8 Hz, 1H, CH), 5.00-5.03 (br, 2H, CH$_2$), 6.79-6.80 (s, 2H, CH), 7.25-7.28 (d, J = 8.4 Hz, 2H, ArH), 7.54-7.57 (d, J =
8.4 Hz, 2H, ArH); $^{13}$C NMR (150 MHz, MeOD-d4 and CDCl$_3$ mix) 18.3 (CH$_3$), 19.4 (CH$_3$), 26.7 (CH$_2$), 29.5 (CH$_2$), 30.7 (CH$_2$), 30.8 (CH), 36.8 (CH$_2$, PEG), 39.3 (CH$_2$), 39.8 (CH$_2$), 40.1 (CH$_2$, PEG), 53.7 (CH), 59.7 (CH), 66.9 (CH$_2$), 67.5 (CH$_2$, PEG), 69.8 (CH$_2$, PEG), 70.4 (CH$_2$, PEG), 70.5 (CH$_2$, PEG), 70.6 (CH$_2$, PEG), 70.7-70.8 (overlapped CH$_2$, PEG), 71.5 (CH), 77.9 (C overlapped with CDCl$_3$) 120.4 (ArCH), 129.1 (ArCH), 132.6 (ArC), 134.8 (CH), 138.3 (ArC), 157.2 (CO), 161.0 (CO), 167.6 (CO), 170.9 (CO), 171.0 (CO), 172.6, (CO), 173.4 (CO). LRMS (NSI) 608 (100, [M+NH$_4$+H]$^+$), 1219 (6, [M+Na]$^+$); HRMS (NSI) calcd. for C$_{55}$H$_{88}$N$_8$O$_{21}$Na [M+Na]$^+$ 1219.5962, observed: 1219.5960.
To an oven-dried RBF was added a solution of diBrPD-Me/-Acid 20 (50 mg, 146 µmol) dissolved in dry THF (2 mL) and the stirred solution cooled to 4 °C with an ice/water bath. DCC (28.8 mg, 140 µmol) was added and stirring continued at 4 °C for 10 min. Pentafluorophenol (14.6 µL, 140 µmol) was then added and the reaction mixture allowed to reach ambient temperature (=20 °C) and stirred for 2 h. The reaction mixture was then filtered by vacuum filtration through a sinter funnel and any solids washed with cold THF. The filtrate was concentrated in vacuo then taken up in cold THF and filtered again. The filtration-resuspension process was repeated until concentrating the filtrate resulted in oil residue only. The PFP-activated ester was dissolved in dry MeCN (1 mL) and to the solution was added NH₂-PEG₁₂-CO₂Bu (109 mg, 161 µmol) The reaction mixture was stirred at ambient temperature for 16 h before concentrating in vacuo to leave an oily residue, which
was purified by flash column chromatography (CH$_2$Cl$_2$/EtOAc/MeOH 8:4:0 to 8:4:0.6 to 8:2:1) to afford the title compound 21 as a light brown oil (61 mg, 61 µmol, 42%). Characterisation data: FTIR $\nu_{\text{max}}$ (cm$^{-1}$): 2869, 1727, 1688, 1640, 1106. $^1$H NMR (500 MHz, CDCl$_3$): 1.43 (s, 9H, tBu CH$_3$), 2.48 (t, $J = 6.6$ Hz, 2H, PEG CH$_2$CO$_2$), 3.43-3.48 (m, 2H, PEG CH$_2$NH), 3.56-3.66 (overlapped m, 49H, PEG CH$_2$ and PD NCH$_3$), 3.69 (t, $J = 6.6$ Hz, 2H, PEG CH$_2$CH$_2$CO$_2$), 4.85 (s, 2H, PD NCH$_2$), 7.53 (br, 1H, NH). $^{13}$C NMR (125 MHz, CDCl$_3$) 28.1 (C(CH$_3$)$_3$), 34.7 (NCH$_3$), 36.3 (CH$_2$CO$_2$), 39.7 (CH$_3$NH), 50.2 (CH$_2$N), 66.9 (CH$_2$CH$_2$CO$_2$), 69.6 (CH$_2$, PEG), 69.8 (CH$_2$, PEG), 70.1 (CH$_2$, PEG), 70.2 (CH$_2$, PEG), 70.3-70.6 (overlapped CH$_2$, PEG), 80.5 (C(CH$_3$)$_3$), 134.8 (ArCBr), 136.6 (ArCBr), 152.4 (ArCO), 153.4 (ArCO), 165.7 (NHCO), 170.9 (CO$_2$).
To a solution of ester 21 (40 mg, 0.04 mmol) in CH₂Cl₂ (1 mL) was added TFA (614 µL, 8.02 mmol) and the reaction mixture stirred at room temperature for 2 h. The mixture was concentrated in vacuo and azeotroped with toluene (3x 5 mL) to ensure removal of excess TFA. A portion of the resulting acid (10.3 mg, 10.93 µmol) was dissolved in MeCN (200 µL), to which was added EEDQ (5.4 mg, 21.86 µmol) and the reaction mixture was stirred at 20 °C for 5 min before addition of MMAE.TFA (10 mg, 12.02 µmol). Stirring continued at 20 °C for 16 h. Reaction mixture was concentrated in vacuo and the residue purified by flash column chromatography (CH₂Cl₂/EtOAc/MeOH 0:9:1 until MMAE eluted, then 6:3:1 to 8:2:1) to give title compound 8 as a light brown viscous oil (9 mg, 51%). Characterisation data: ¹H NMR (500 MHz, CDCl₃ and MeOD-d₄ mix) 0.81-0.85 (m MMAE), 0.85-0.95 (m, MMAE), 0.96-0.98 (m, 3H, MMAE), 1.00-1.08 (m, 5H, MMAE), 1.23-1.29 (m, MMAE), 1.33-1.41 (m, MMAE),
1.82-1.87 (m, MMAE), 1.97-2.09 (m, H₂O and MMAE), 2.17-2.25 (m, MMAE), 2.36-2.50 (m, MMAE), 2.57-2.76 (m, MMAE), 2.84-2.93 (m, MMAE), 2.98-3.04 (m, MMAE), 3.11 (br, MMAE), 3.27-3.34 (m, MMAE), 3.37-3.39 (m, MMAE), 3.40-3.42 (m, MMAE), 3.44-3.48 (m, MMAE), 3.47-3.50 (m, MMAE), 3.50-3.55 (m, 1H, MMAE), 3.57-3.59 (t, J = 5.3 Hz, 2H, PEG CH₂), 3.60-3.75 (overlapped m, PEG CH₂, MMAE and PD NCH₃), 3.75-3.82 (overlapped m, 3H, MMAE CH and PEG CH₂), 3.82-3.86 (m, 2H, PEG CH₂), 4.03-4.09 (m, 2H, MMAE), 4.15-4.18 (m, 2H, MMAE), 4.25-4.29 (m, 2H, MMAE), 4.55-4.75 (m, 3H, MMAE), 4.85 (s, 2H, PD NCH₂), 4.95-4.96 (d, J = 3.0 Hz, 1H, MMAE), 6.56 (d, J = 6.6 Hz, 1H, NH), 6.62 (d, J = 9.4 Hz, 1H, NH), 7.32-7.39 (m, 5H, ArH MMAE), 7.86 (br, 1H, NH). ¹³C NMR (125 MHz, CDCl₃ and MeOD-d₄ mix) 10.9 (CH₃, MMAE), 13.9 (CH₃, MMAE), 14.5 (CH₃, MMAE), 18.5 (CH₃, MMAE), 19.3 (CH₃, MMAE), 22.7 (CH₃, MMAE), 24.9 (CH₂, MMAE), 25.0 (CH₂, MMAE), 25.9 (CH₂, MMAE), 29.3 (CH, MMAE), 29.7 (CH₃, MMAE), 30.7 (CH, MMAE), 31.9 (CH, MMAE), 33.4 (CH, MMAE), 34.1 (CH₂CON, PEG), 34.7 (NCH₃, PD), 37.7 (CH₂, MMAE), 39.6 (CH₂NH, PEG), 44.9 (CH, MMAE), 47.8 (CH₂, MMAE), 50.1 (NCH₂, PD), 51.6 (CH, MMAE), 53.9 (CH, MMAE), 58.0 (OCH₃, MMAE), 60.1 (CH, MMAE), 60.9, (OCH₃, MMAE), 67.3 (OCH, MMAE), 70.0 (CH₂, PEG), 70.2-70.5 (overlapped CH₂, PEG), 75.8 (OCH, MMAE), 78.2 (CH, MMAE), 81.9 (OCH, MMAE), 126.3 (ArCH, MMAE), 127.2 (ArC, MMAE), 128.0 (ArCH, MMAE), 134.8 (ArCBr), 136.6 (ArCBr), 141.3 (ArC, MMAE), 152.4 (ArCO), 153.4 (ArCO), 164.5 (PD NCH₂CO), 169.7 (CO) 170.6 (CO, MMAE), 172.1 (CO, MMAE), 172.8 (CO, MMAE), 174.6 (CO, MMAE). LRMS (NSI) 304 (100), 838 (40, [M+2NH₄]²⁺), 829 (38, [M+H+NH₄]²⁺); HRMS (NSI) calcd. for C₇₃H₁₂₉Br₂N₉O₂₃ [M+H+NH₄]²⁺ 828.8779, observed: 828.8780.
To a solution of BocNH-PEG$_{12}$-CO$_2$H (30 mg, 42.0 µmol) in dry CH$_2$Cl$_2$ (1000 µL) was added HBTU (15.9 mg, 42.0 µmol) and HOBt (0.1 mg, 4.2 µmol) followed by DIPEA (36.4 µL, 210 µmol). The reaction mixture was stirred at 20 °C for 5 min before addition of a solution of propargylamine (8.0 µL, 125.0 µmol) in dry CH$_2$Cl$_2$ (1000 µL) and stirring continued for 5 h. Reaction mixture was concentrated in vacuo and then taken up in CH$_2$Cl$_2$ (2 mL) and concentrated again (2x) to eliminate excess propargylamine. Residue taken up in CH$_2$Cl$_2$ (20 mL) and washed with 15% citric acid (10 mL), sat. NaHCO$_3$ aq. solution (10 mL), and H$_2$O (10 mL). Organic layer was dried (MgSO$_4$) and concentrated in vacuo. Crude material was purified by flash column chromatography (CH$_2$Cl$_2$/MeOH 100:0 to 95:5) to give title compound 22 as a colourless oil (21 mg, 66%). Characterisation data: FTIR $\nu_{\text{max}}$ (cm$^{-1}$): 3305, 2869, 1707, 1667, 1249, 1100, 844. $^1$H NMR (500 MHz, CDCl$_3$): 1.42 (s, 9H, tBu CH$_3$), 2.20 (t, J = 2.3 Hz, 1H, CCH), 2.48 (t, J = 5.7 Hz, 2H, PEG CH$_2$CONH), 3.28-3.31 (m, 2H, PEG CH$_2$), 3.51-3.53 (m, 2H, PEG CH$_2$), 3.59-3.66 (overlapped m, 45H, PEG CH$_2$ and PD NCH$_3$), 3.70-3.72 (t, J =
5.7 Hz, 2H, PEG CH₂), 4.02 (dd, J = 5.2, 2.3 Hz, 2H, CH₂CC), 5.11 (br, 1H, NH), 7.00 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): 28.5 (tBu CH₃), 29.0 (CH₂CC), 36.8 (CH₂CH₂CONH), 40.4 (CH₂NHCO₂), 67.1 (CH₂CH₂CONH), 70.3 (PEG CH₂), 70.6-70.7 (overlapped PEG CH₂), 71.1 (CCH), 79.2 (C(CH₃)₃), 80.2 (CCH), 156.1 (NHCO₂), 171.5 (NHCOCH₂). LRMS (ESI⁺) 772 (100, [M+NH₄⁺]), 755 (95, [M+H⁺]); HRMS (ESI⁺) calcd. for C₃₅H₆₇N₂O₁₅ [M+H⁺] 755.4542, observed: 755.4543.
To an oven-dried RBF was added a solution of diBrPD-Me-/Acid 20 (9.5 mg, 28 µmol) in dry THF (200 µL). The stirred solution was cooled to 4 °C with an ice/water bath before addition of DCC (5.73 mg, 28 µmol) and stirring continued at 4 °C for 10 min. Pentafluorophenol (2.91 µL, 28 µmol) was then added and the reaction mixture allowed to reach ambient temperature (≈20 °C) and stirred for 2 h. The reaction mixture was then filtered through a pipette with celite plug and solids washed with cold THF. The filtrate was concentrated in vacuo then taken up in a minimum volume of cold THF and filtered again to ensure no precipitates remained. The PFP-activated ester was then dissolved in dry MeCN (200 µL).

To a solution of BocNH-PEG12-propargylamide 22 (21 mg, 28 µmol) in CH2Cl2 (950 µL) was added TFA (50 µL, 654 µmol) and the reaction mixture stirred at 20 °C for 90 min. The mixture was concentrated in vacuo and re-suspended in CH2Cl2 (2 mL) repeatedly (5x) to evaporate any residual TFA. The remaining oil was dissolved in MeCN (500 µL), to which was added DIPEA (244 µL, 1400 µmol (50 eq.)), and the mixture was added to the solution of PFP-activated ester. The reaction mixture was stirred at ambient temperature for 16 h before concentrating in vacuo. Purification of the oily residue by flash column chromatography (CH2Cl2/EtOAc/MeOH 1:1:0 to 9:9:2 to 9:9:3) resulted in co-elution of two major fractions, which were separated by preparative TLC (CH2Cl2/EtOAc/MeOH 8:2:1) to give title compound 10 as a light brown viscous oil (14 mg, 51%) - NMR showed product to contain hydrocarbon impurities.

Characterisation data: FTIR νmax (cm⁻¹): 2149, 1647, 1390, 1099, 662. ¹H NMR (500 MHz, CDCl3): 2.22 (t, J = 2.3 Hz, 1H, CCH), 2.49 (t, J = 5.7 Hz, 2H, PEG CH₂CONH), 3.45-3.48 (m, 2H, PEG CH₂), 3.56-3.58 (m, 2H, PEG CH₂), 3.61-3.65 (overlapped m, 47H, PEG CH₂ and PD NC₃H₃), 3.72 (t, J = 5.7 Hz, 2H, PEG CH₂), 4.02 (dd, J = 5.2, 2.3 Hz, 2H, CH₂CC), 4.85 (s, 2H, NCH₂CONH), 7.04 (br, 1H, NH), 7.85 (br, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): 29.0 (CH₂CC), 34.8 (NCH₃), 36.8 (CH₂CH₂CONH), 39.7 (CH₂CH₂NHCO), 50.1 (NCH₂CONH), 67.1 (CH₂CH₂CONH), 69.7 (PEG CH₂), 70.1 (PEG CH₂), 70.3-70.7 (overlapped PEG CH₂), 71.2 (CCH), 80.2 (CCH), 135.0 (ArCBr), 136.0 (ArCBr), 152.5 (ArCO), 153.5 (ArCO),
165.7 (NCH$_2$CONH), 171.6 (NHC=OCH$_2$CH$_2$). LRMS (NSI) 217 (100), 304 (91), 996 (3, [M+NH$_4$]$^+$);
HRMS (NSI) calcd. for C$_{37}$H$_{66}$Br$_2$N$_3$O$_6$ [M+NH$_4$]$^+$: 994.2866, observed: 994.2855.
References

1. G. Candiano, M. Bruschi, L. Musante, L. Santucci, G. M. Ghiggeri, B. Carnemolla, P. Orecchia, L. Zardi and P. G. Righetti, *Electrophoresis*, 2004, **25**, 1327-1333.

2. Workman P, Aboagye EO, Balkwill F, et al. *Guidelines for the welfare and use of animals in cancer research. Br J Cancer*. 2010;102:1555–1577.

3. Vassileva V, Allen CJ, Piquette-Miller M. *Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther.* 2008;7:630–637.

4. Ullman-Culleré MH, Foltz CJ. *Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci.* 1999;49:319–323.

5. J. P. M. Nunes, M. Morais, V. Vassileva, E. Robinson, V. S. Rajkumar, M. E. B. Smith, R. B. Pedley, S. Caddick, J. R. Baker and V. Chudasama, *Chem. Commun.*, 2015, **51**, 10624-10627.

6. F. F. Schumacher, J. P. M. Nunes, A. Maruani, V. Chudasama, M. E. B. Smith, K. A. Chester, J. R. Baker and S. Caddick, *Org. Biomol. Chem*, 2014, **12**, 7261-7269.

7. S. O. Doronina, B. E. Toki, M. Y. Torgov, B. A. Mendelsohn, C. G. Cerveny, D. F. Chace, R. L. DeBlanc, P. R. Gearing, T. D. Bovee, C. B. Siegall, J. A. Francisco, A. F. Wahl, D. L. Meyer and P. D. Senter, *Nat. Biotech.*, 2003, **21**, 778-784.